Combined archive search across FBI Vault, SPLC, PHMPT, ACIP, NIH grants, the Federal Writers' Project, and other collections we've ingested.
KEITH R JEROME · FRED HUTCHINSON CANCER CENTER · 2024 · $862,440 — Project Summary Chronic Hepatitis B virus (HBV) infection (CHB) affects hundreds of millions of people across the world. Despite effective vaccines, and antiviral therapies that can suppress viral replication, these infections are largely incurable, and new therapies for CHB are desperately needed. …
Ken A Halvorsen · STATE UNIVERSITY OF NEW YORK AT ALBANY · 2024 · $84,134 — Project Summary Our vision is to develop, apply, and advance new technologies in the broad thematic program of the manipulation of nucleic acids. The research largely focuses on RNA-based applications, which is both driven and enhanced by our unique environment at The RNA Institute, enabling easy co…
Eleftherios Michailidis · EMORY UNIVERSITY · 2024 · $74,814 — Project Summary There are approximately a quarter of a billion people worldwide chronically infected with hepatitis B virus (HBV) who are at risk of developing liver cirrhosis and hepatocellular carcinoma. The loss of life due to HBV-related complications each year is about 820,000 people. At the sa…
Clair Crewe · WASHINGTON UNIVERSITY · 2024 · $622,000 — Project Summary Current paradigms of drug development have made remarkable progress in treating and preventing disease by effecting the function of a single target enzyme, or receptor with specificity. However, many chronic diseases like type 2 diabetes, Alzheimer’s disease, and cardiovascular dise…
Charles M Rice · ROCKEFELLER UNIVERSITY · 2024 · $846,776 — Project Summary The yellow fever 17D live-attenuated vaccine has been administered to millions of people and is a highly successful and safe vaccine providing essentially life-long protection. However, the mechanisms of attenuation are poorly understood, and rare individuals suffer from sometimes f…
Barton F. Haynes · DUKE UNIVERSITY · 2024 · $3,169,510 — Nonhuman primate studies for development of a prototype HIV vaccine that induces broadly neutralizing antibodies Barton Haynes, MD- PI Sampa Santra, PhD- Co-Investigator The Duke CHAVD has had two major breakthroughs this year in our ability to use rhesus macaques for the study of vaccine-induced bn…
Carlos Enrique Catalano · UNIVERSITY OF COLORADO DENVER · 2024 · $726,000 — PROJECT SUMMARY Newly emerging and long-standing infectious challenges, including arboviruses, Ebola virus and pandemic coronaviruses (CoVs), among others, pose serious public health concerns. Additionally, the potential use of biological agents as weapons of mass destruction poses an ongoing threat…
Kartik Chandran · ALBERT EINSTEIN COLLEGE OF MEDICINE · 2024 · $13,946,446 — The overarching goal of PROVIDENT (Prepositioning Optimized Strategies for Vaccines and Immunotherapeu- tics against Diverse Emerging Infectious Threats) is to deliver “plug-and-play” vaccine and therapeutic an- tibody blueprints for emerging enveloped RNA viruses belonging to three families—Nairovi…
GUANGMING ZHONG · UNIVERSITY OF TEXAS HLTH SCIENCE CENTER · 2024 · $2,202,675 — Abstract This proposal is to produce IND-enabling data for supporting clinical trials of an attenuated clone of the mouse-adapted Chlamydia muridarum (CM) as a novel oral vaccine known as intrOv for protecting humans from sexually transmitted infection with Chlamydia trachomatis (CT). Extensive sear…
Ryan Englander · UNIVERSITY OF CONNECTICUT SCH OF MED/DNT · 2024 · $53,974 — PROJECT SUMMARY/ABSTRACT Non-small cell lung cancer (NSCLC) is the leading cause of cancer mortality in the United States. Immune checkpoint inhibitors (ICIs) like anti-PD-1 have increased overall survival in NSCLC, but most patients still do not respond to treatment. Cancer vaccines that target tum…
Gabriel D Victora · ROCKEFELLER UNIVERSITY · 2024 · $797,082 — PROJECT SUMMARY Generation of high affinity antibodies in germinal centers (GCs) is a critical step in a wide variety of clinically relevant processes, from protection against pathogens by prior infection or vaccination to the development of allergies and autoimmune diseases. Antibody affinity matur…
Paul Stephen Keim · NORTHERN ARIZONA UNIVERSITY · 2024 · $1,474,679 — OVERALL Section Title: Early in vivo expressed antigens and their role in virulence, immune response, and vaccines for coccidioidomycosis. SUMMARY Coccidioidomycosis, also known as Valley Fever (VF), is an important fungal disease caused by two different Coccidioides species that results in regional…
NASSER Khaled ALTORKI · WEILL MEDICAL COLL OF CORNELL UNIV · 2024 · $1,060,438 — Overall Component: Project Summary/Abstract The overall goal of CAP-IT Center for RNA Immunoprevention (CRI) is to pre-clinically delineate, formulate and validate liponanoparticle RNA (LNP RNA) vaccines for precision prevention of individuals with increased cancer risk. The PI is Dr. Lipkin, an est…
Hannah Frizzell · ORLANCE, INC. · 2024 · $300,000 — PROJECT SUMMARY COVID-19 launched mRNA vaccines to the forefront as the most effective and rapid strategy to respond to the pandemic. mRNA vaccines require formulation in lipid nanoparticles (LNPs) to protect the mRNA from degradation and to achieve efficient intracellular delivery. However, LNP-mRN…
Todd Wallach · ONCOSTING LLC · 2024 · $270,176 — Abstract Tuberculosis (TB) remains the topmost killer among infectious diseases globally, and is one of the world’s most significant medical challenges. Approximately one quarter of the world population has been infected with Mycobacterium tuberculosis (M.tb), the majority being latent cases that co…
James Matthew Burns · DREXEL UNIVERSITY · 2024 · $738,445 — The heavy burden of Plasmodium falciparum and Plasmodium vivax malaria drove international efforts to coordinate and integrate tools and programs for mosquito vector control, rapid diagnosis, and drug treatment. Success has been significant but may be approaching a limiting boundary. The effort to d…
Siyuan Ding · WASHINGTON UNIVERSITY · 2024 · $155,500 — Project Summary Small bowel intestinal epithelial cells (IECs) are the first line of defense against human enteric viruses, the most common and leading causes of diarrhea and death in infants and young children. How IECs communicate with intraepithelial lymphocytes (IELs) in the small intestine and…
Pablo Penaloza-MacMaster · NORTHWESTERN UNIVERSITY AT CHICAGO · 2024 · $498,659 — PROJECT SUMMARY: Developing a vaccine against HIV is thus a research priority, but it has been difficult in part because vaccines have not been able to generate sufficient antiviral immunity able to prevent infection. Our prior research using Ad5-vectored vaccines show that vaccine prime fractionati…
Yogesh K Gupta · UNIVERSITY OF TEXAS HLTH SCIENCE CENTER · 2024 · $584,674 — Modified Project Summary/Abstract Section The massive global pandemic with high morbidity and mortality makes Severe Acute Respiratory Syndrome coronavirus-2 (SARS-CoV-2) one of the deadliest viruses in recent history. It is especially noteworthy for hijacking the normal operations of human cells. T…
Roger L Shapiro · HARVARD UNIVERSITY D/B/A HARVARD SCHOOL OF PUBLIC HEALTH · 2024 · $1,195,048 — Overall Project Summary/Abstract Antiretroviral treatment (ART) options for pregnant women and children living with HIV have fallen behind those for adults, reflecting the substantial research gap for modern ART regimens in these groups. Safety and efficacy studies of specific ART regimens in pregna…